Today, Tilray announced that it has successfully exported medical cannabis products to the state of Victoria in Australia.
According to the government of Victoria, 29 critically ill children will become the first patients in the Australian state to legally access medical cannabis when the Tilray products are distributed. Tilray products are currently available to certain patients in other Australian states and in New Zealand under special access pathways for unapproved medicines.
“This is too important to wait. That’s why we’re doing everything we can to make sure those families in the greatest need can access this life-changing treatment for their kids as soon as possible,” said Premier Daniel Andrews of Victoria, Australia.
“We are proud to be able to offer patients in need access to high-quality, pharmaceutical-grade medical cannabis products,” said Dr. Catherine Jacobson, Tilray director of clinical research. “In this case, the government of Victoria has elected to fast-track the introduction of a medical cannabis product containing a specific cannabinoid, cannabidiol (CBD), for the treatment of seizures in children who have not responded to formally approved anti-seizure drugs. We welcome the opportunity to provide this potentially life-saving treatment to patients in need.”
Tilray currently supplies pharmaceutical-grade medical cannabis products – including whole flower, oils and capsules – to thousands of patients, physicians, pharmacies, hospitals, governments and researchers around the world for commercial, compassionate access and research purposes.